Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines

  • 495 Accesses

  • 6 Citations

Abstract

Purpose

Epigenetic therapy has had a significant impact on the management of haematologic malignancies. The aim of this study was to assess whether 5-aza-CdR and TSA inhibit the growth of leukaemia cells and induce caspase-3-dependent apoptosis by upregulating RUNX3 expression.

Methods

K562 and Reh cells were treated with 5-aza-CdR, TSA or both compounds. RT-PCR and Western blot analyses were used to examine the expression of RUNX3 at the mRNA and protein levels, respectively. Immunofluorescence microscopy was used to detect the cellular location of RUNX3. Additionally, after K562 cells were transfected with RUNX3, apoptosis and proliferation were studied using Annexin V staining and MTT assays.

Results

The expression of RUNX3 in leukaemia cell lines was markedly less than that in the controls. Demethylating drug 5-aza-CdR could induce RUNX3 expression, but the combination of TSA and 5-aza-CdR had a greater effect than did treatment with a single compound. The combination of 5-aza-CdR and TSA induced the translocation of RUNX3 from the cytoplasm into the nucleus. TSA enhanced apoptosis induced by 5-aza-CdR, and Annexin V and Hoechst 33258 staining showed that the combination induced apoptosis but not necrosis. Furthermore, apoptosis was dependent on the caspase-3 pathway. RUNX3 overexpression in K562 cells led to growth inhibition and apoptosis and potentiated the effects of 5-aza-CdR induction.

Conclusion

RUNX3 plays an important role in leukaemia cellular functions, and the induction of RUNX3-mediated effects may contribute to the therapeutic value of combination TSA and 5-aza-CdR treatment.

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Abbreviations

RUNX3:

Runt-related transcription factor 3

CpG:

Cytosine phosphate guanine

5-aza-CR:

5-aza-cytidine

5-aza-CdR:

5-aza-2-deoxycytidine

CML:

Chronic myeloid leukaemia

References

  1. Agirre X, Novo FJ, Calasanz MJ et al (2003a) TP53 is frequently altered by methylation, mutation, and/or deletion in acute lymphoblastic leukaemia. Mol Carcinog 38:201–208

  2. Agirre X, Vizmanos JL, Calasanz MJ et al (2003b) Methylation of CpG dinucleotides and/or CCWGG motifs at the promoter of TP53 correlates with decreased gene expression in a subset of acute lymphoblastic leukemia patients. Oncogene 22:1070–1072

  3. Bae SC, Takahashi E, Zhang YW, Ogawa E, Shigesada K, Namba Y, Satake M, Ito Y (1995) Cloning, mapping and expression of PEBP2 alpha C, a third gene encoding the mammalian Runt domain. Gene 159:245–248

  4. Balmain A (2002) Cancer: new-age tumor suppressors. Nature 417:235–237

  5. Bangsow C, Rubins N, Glusman G et al (2001) The RUNX3 gene-sequence structure and regulated expression. Gene 279:221–232

  6. Banin S, Moyal L, Shieh S et al (1998) Enhanced phosphorylation of P53 by ATM in response to DNA damage. Science 281:1674–1677

  7. Baylin SB, Herman JG (2000) DNA hypermethylation in tumorigenesis. Trends Genet 16:168–174

  8. Bird A (2002) DNA methylation patterns and epigenetic memory. Genes Dev 16:6–21

  9. Bird AP, Wolffe AP (1999) Methylation-induced repression belts, braces, and chromatin. Cell 99:451–454

  10. Chi KC, Margaret HLN (2008) Transcriptional repression of the gene RUNX3/AML2 by the t (8:21) and inv (16) fusion proteins in acute myeloid leukemia. Blood 112:3391–3402

  11. Chi XZ, Yang JO, Kim WJ, Ito Y, Bae SC (2005) RUNX3 suppresses gastric epithelial cell growth by inducing P21WAP1/Cip1 expression in cooperation with TGF-β-activated SMAD. Mol Cell Biol 25:8097–8107

  12. Claus R, Lubbert M (2003) Epigenetic targets in hematopoietic malignancies. Oncogene 22:6489–6496

  13. Cordenonsi M et al (2007) Phosphorylation integration of TGF-ß and Ras/MAPK signaling through P53. Science 315:840–843

  14. Corn PG, Smith BD, Ruckdeschel ES, Douglas D, Baylin SB, Herman JG (2000) E-cadherin expression is silenced by 5CpG island methylation in acute leukemia. Clin Cancer Res 6:4243–4248

  15. Cornelius M, Rebekka G, Claudia M et al (2007) Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. PNAS 104:4594–4599

  16. Dokmanovic M, Marks PA (2005) Prospects: histone deacetylase inhibitors. J Cell Biochem 96:293–304

  17. Egger G, Liang G, Aparicio A, Jones PA (2004) Epigenetics in human disease and prospects for epigenetic therapy. Nature 429:457–463

  18. el-Deiry WS, Tokino T, Velculescu VE et al (1993) WAF1, a potential mediator of P53 tumor suppression. Cell 75:817–825

  19. Esteller M (2003) Profiling aberrant DNA methylation in hematologicneoplasms: a view from the tip of the iceberg. Clin Immunol 109:80–88

  20. Gardiner-Garden M, Frommer M (1987) CpG islands in vertebrate genomes. J Mol Biol 196:261–282

  21. Hanai J, Chen LF, Kanno T, Ohtani-Fujita N, Kim WY, Guo WH, Imamura T, Ishidou Y, Fukuchi M, Shi MJ, Ito Y (1999) Interaction and functional cooperation of PEBP2/CBF with Smads. Synergistic induction of the immunoglobulin germline Cpromoter. J Biol Chem 274:31577–31582

  22. Harris CA, Eugane MJ (2001) BH3-only Bcl-2 family members are coordinately regulated by the JNK pathway and require Bax to induce apoptosis in neurons. J Biol Chem 276:37754–37760

  23. Herman JG, Jen J, Merlo A, Baylin SB (1996) Hypermethylation-associated inactivation indicates a tumor suppressor role for p15 (INK4B). Cancer Res 56:722–727

  24. Herman JG, Civin CI, Issa JP, Collector MI, Sharkis SJ, Baylin SB (1997) Distinct patterns of inactivation of p15INK4B and p16INK4A characterize the major types of hematological malignancies. Cancer Res 57:837–841

  25. Huang DC, Strasser A (2000) BH3-only proteins—essential initiators of apoptotic cell death. Cell 103:839–842

  26. Inoue K, Ozaki S, Shiga T, Ito K, Masuda T, Okado N, Iseda T, Kudo N, Ito Y (2002) RUNX3 controls the axonal projection of proprioceptive dorsal root ganglion neurons. Nat Neurosci 5:946–954

  27. Ito Y, Miyazono K (2003) RUNX transcription factors as key targets of TGF-β superfamily signaling. Curr Opin Genet Dev 13:43–47

  28. Ito K, Liu Q, Salto-Tellez M, Yano T, Tada K, Ida H, Huang C, Shah N, Inoue M, Yeoh KG, Ito Y (2005) RUNX3, a novel tumor suppressor, is highly inactivated in gastric cancer by protein mislocalization. Cancer Res 65:7743–7750

  29. Jahangeer S, Elliott RM, Henneberry RC (1982) β-Adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. Biochem Biophys Res Commun 108:1434–1440

  30. Kosei I, Anthony C-BL, Manuel S-T et al (2008) RUNX3 attenuates β-catenin/T cell factors in intestinal tumorigenesis. Cancer Cell 14:226–237

  31. Krug U, Ganser A, Koeffler HP (2002) Tumor suppressor genes in normal and malignant hematopoiesis. Oncogene 21:3475–3495

  32. Li QL, Ito K, Sakakura C et al (2002) Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109:113–124

  33. Minucci S, Pelicci PG (2006) Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 6:38–51

  34. Mudit V, Joanna F (2009) Surfactant protein DNA methylation: a new entrant in the field of lung cancer diagnostics? Oncol Rep 21(1):3–21

  35. Nickerson JA (2001) Experimental observations of a nuclear matrix. J Cell Sci 114:463–474

  36. Okorokov AL, Rubbi CP, Metcalfe S, Milner J (2002) The interaction of P53 with the nuclear matrix is mediated by F-actin and modulated by DNA damage. Oncogene 21:356–367

  37. Puig-Kroger A, Corbi A (2006) RUNX3: a new player in myeloid gene expression and immune response. J Cell Biochem 98:744–756

  38. Quesnel B, Guillerm G, Vereecque R et al (1998) Methylation of the p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985–2990

  39. Sandhya P, Syed AA, Christopher D (2009) Subnuclear targeting of the RUNX3 tumor suppressor and its epigenetic association with mitotic chromosomes. J Cell Physiol 218:473–479

  40. Takai D, Jones PA (2003) The CpG island searcher: a new WWW resource. In SilicoBiol 3:235–240

  41. Wei D, Gong W, Oh SC et al (2005) Loss of RUNX3 expression significantly affects the clinical outcome of gastric cancer patients and its restoration causes drastic suppression of tumor growth and metastasis. Cancer Res 65:4809–4816

Download references

Author information

Correspondence to Dong-Jun Lin.

Additional information

Feng-Xian Zhai and Xiang-Fu Liu contributed equally to this work.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Zhai, F., Liu, X., Fan, R. et al. RUNX3 is involved in caspase-3-dependent apoptosis induced by a combination of 5-aza-CdR and TSA in leukaemia cell lines. J Cancer Res Clin Oncol 138, 439–449 (2012). https://doi.org/10.1007/s00432-011-1113-y

Download citation

Keywords

  • Runt-related transcription factor 3 (RUNX3)
  • Chronic myeloid leukaemia (CML)
  • 5-aza-2-deoxycytidine (5-aza-CdR)
  • TSA (trichostatin A)